您好,欢迎来到上海士研管理咨询有限公司
产业峰会 演讲局 专家智库服务 峰会活动服务 整合营销服务
  • 产业峰会:
    以专业团队对产业和市场客观详实地调研为前提,拥有战略性、系统性、全球性的基因,汇集了领导者关注的热点话题与领袖代表,为您提供“一站式”的对话、分享、社交平台!
  • 演讲局:
    致力于为全球企业和机构提供主题演讲家、高管大师班、董事会顾问,每项服务都提供了一种更深入、更具互动性的体验,尤其是针对较小的精选受众和关键个人。我们拥有最具影响力的商业领袖和顶级专家的资源,他们是各自领域的最杰出的代表。我们的团队由经验丰富的演讲和活动经理组成,我们注重建立长期而深入的伙伴关系。
  • 专家智库服务:
    中国领先的行业专家知识信息服务供应商,为需要专业洞见的商业决策者匹配具有一手经验的行业专家,助力他们以更加明确的目标和坚定的信心做出决策。我们有60万余名专家顾问遍布二十多个行业,而且每天还在增加!
  • 峰会活动服务:
    致力于成为全球最专业的产业峰会活动提供商,为企业和机构的产业性峰会活动提供一站式专业服务,包括调研策划、定制邀请、营销推广、运营组织、项目管理、直播与数字化会议等,每项服务都由经验丰富的专业团队匹配长期沉淀的产业资源予以卓越执行,我们注重建立长期而深入的伙伴关系。
  • 整合营销服务:
    致力于成为全球领先的2B营销服务机构,聚焦产业高端活动、内容、渠道的建设与沉淀,为客户提供一站式整合营销解决方案,助力企业线上线下获客与品牌筑造。我们深信专业团队匹配产业资源带来卓越执行,我们注重建立长期而深入的伙伴关系。
嘉宾信息
发布时间: 2021 - 08 - 16
点击次数: 0
所属职位: 全球研发总裁
所属公司: 江苏恒瑞医药股份有限公司
个人简介:
德国Tubingen大学获有机化学博士,后赴美国Vanderbilt大学从事博士后研究。在加入恒瑞医药前,张连山博士先后在美国礼来和Marcadia Biotech等国际知名药企担任要职,其中在礼来先后任高级化学家、研究顾问及首席研究科学家等。自1988年至今,他从事多肽方法学和新药研发工作三十余年,在糖尿病治疗药物方面极有造诣;在国际学术期刊上发表学术文章60余篇,申请专利160余项。加入恒瑞医药后,他带领团队研发了一系列具有国际竞争力的创新药,其中8个1类创新药品种已获批上市,多个重磅产品已递交上市申请,180多项临床研究正在国内外开展,研发管线全面覆盖国际热门靶点和存在重大未满足临床需求的疾病领域。 Dr. Lianshan Zhang holds the position of Senior Vice President and Global R&D President of Jiangsu Hengrui Medicine. Hengrui is widely recognized as the domestic leader in pharmaceutical R&D innovation in China. In 2010, Dr. Zhang joined Hengrui and takes the responsibility for R&D strategy and management of dozens of NMEs across the globe. Prior to Hengrui, he was a senior research executive at Marcadia Biotech. From 1998 to 2008, Dr. Zhang was engaged in the discovery and development of peptide/protein therapeutics for the treatment of diabetes and obesity and successfully delivered multiple clinical candidates.  Dr. Lianshan Zhang obtained his undergraduate degree in Medicinal Chemistry from China Pharmaceutical University and his Ph.D. in Organic Chemistry at the University of Tubingen. He conducted his post-doctoral research at University of Tubingen and Vanderbilt University.
发布时间: 2021 - 08 - 16
点击次数: 0
所属职位: 负责人,罗氏上海创新中心
所属公司: 罗氏上海创新中心
个人简介:
沈宏博士本科毕业于北京大学,在斯坦福大学获化学博士。在美国默沙东公司工作9年后,2012年沈宏博士加盟罗氏上海创新中心,现任研发中心负责人。现在沈宏博士主要参与免疫,肿瘤,抗感染疾病领域的药物研发,并曾经在动脉血管硬化症,高血压,糖尿病,血栓,肥胖症以及神经系统领域从事药物研究。他所在的团队为12个临床化合物做出了重要贡献。沈宏博士参于著书3部,发表学术论文逾百篇,为80多项药物发现专利的共同发明人,作过上百次学术报告。沈宏博士是英国皇家化学学会会士,担任多种科学杂志,书籍,和学术会议的科学专家顾问或评委。 Dr. Hong Shen received his B.S. from Peking University and Ph.D. in chemistry from Stanford University. After 9 years working at Merck in the US, he joined Roche Innovation Center Shanghai (RICS) in 2012. He is now the Site Head of RICS. Dr. Shen’s currently mainly focuses on drug discovery and development in the areas of immunology, oncology, and infectious diseases, and he once participated in drug discovery in atherosclerosis, hypertension, diabetes, thrombosis, obesity, and CNS areas. His teams have made significant contributions to 12 clinical compounds. Dr. Shen has contributed to 3 books, more than 100 publications, and over 80 patent applications. He has delivered over 100 invited lectures. Dr. Shen is a Fellow of the Royal Society of Chemistry (FRSC), a reviewer of numerous international journals, and a scientific advisor of 3 journals/book series.
发布时间: 2021 - 08 - 16
点击次数: 0
所属职位: 首席商务官
所属公司: 正大天晴药业集团股份有限公司
个人简介:
朱凌宇博士在国际制药行业已经工作了20年的时间,他先后在跨国制药企业(美国辉瑞公司和强生公司)和本土创新制药企业(贝达药业)主持战略合作及对外投资业务。到目前为止,朱博士完成了28项总价值超过30亿美元的战略合作及对外投资项目,这其中就包括了2014 年 10 月贝达药业对美国 Xcovery公司2千万美金的战略投资并收购了恩沙替尼的中国权益,以及 2013 年5月贝达药业与美国安进公司在中国建立合资企业推动安进公司的帕妥木单抗在中国的注册报批和市场化。  Dr. Zhu has more than 20 years of experience in the pharmaceutical industry and worked with both global pharmaceutical companies (Pfizer and JNJ) and Chinese pharmaceutical company. He has done 28 strategic transactions (total value US$3 billion) including the 2 recent landmark deals in China, the Joint Venture agreement between Amgen and Betta Pharma to commercialize Amgen’s Vectibix (panitumumab) in China for colorectal cancer patients in May 2013, and the US$20 million strategic investment in Xcovery by Betta Pharma and acquired the China right of Ensartinib in October 2014.
发布时间: 2021 - 08 - 16
点击次数: 0
所属职位: 商务拓展副总裁
所属公司: 中山康方生物医药有限公司
个人简介:
陈晨博士在生物制药及全球商务拓展领域深耕多年,在研发外部创新、管线合作、商务拓展等方面有着扎实的经验和实践成果。在加入公司之前,陈博士曾担任默克雪兰诺(‘默克’)医药研发外部创新亚太区负责人,期间通过联络中国和亚太地区制药公司、生物技术公司、专业投资人以及卓越的学术研究中心,推动与默克研发管线的合作机会。陈博士是默克亚洲和中国研发中心的领导成员之一,也是默克在华拓展肿瘤事业和创新合作的核心成员之一。陈博士从英国埃塞克斯大学获得细胞和分子生物学学士学位、英国诺丁汉大学癌症免疫治疗硕士学位、英国帝国理工学院生物化学博士学位。Dr. Michael Chen has dedicated himself to bio-pharmaceutical industry and global business development for years and has extensive experience and practical achievements in external innovation, pipeline cooperation and business development. Before joining Akeso, Dr. Chen worked as Head of External Innovation APAC for Merck KGaA. Dr. Chen led collaborations with local pharmaceutical/biotech companies, investor groups and academic institutions in China and APAC areas. Meanwhile, Dr. Chen was also responsible for the international business development department of Merck in China and APAC areas, carrying out a variety of internal and external business cooperation. Dr. Chen was also one of the leading members of Merck Asia and China research and development center, and one of the core members for expanding Merck’s oncology business and innovation collaboration in China.Dr. Chen received his bachelor’s degree of cell and molecular biology from University of Essex, a master’s degree in cancer immunotherapy from University of Nottingham and a Ph.D. degree in biochemistry from Imperial College London.
微信公众号
领导者网络APP
友情链接
Copyright ©2005 - 2017上海士研管理咨询有限公司
犀牛云提供企业云服务